ClinicalTrials.gg
CompletedNCT05843175MERIT1DUpdated Dec 17, 2025

Maternal ExeRcIse Timing to Optimise Postprandial Glucose in Type 1 Diabetes

An interventional study of Exercise and meal testing (acute stimuli) in Pregnancy in Diabetic and Type 1 Diabetes, sponsored by University of Graz. Completed at 1 site in Austria. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by University of Graz · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Poor glycaemic control in pregnancy is a major factor leading to obstetric complications and future maternal-offspring diseases. This phenomenon is evidenced in women with type 1 diabetes (T1DM), and is worrisome since it is aggravating the disease burden of this and next generations.

Exercise is a promising tool to improve glucose control during pregnancy and thus avoid adverse consequences.

The MERIT1D study will explore when is exercise (before or after lunch) more effective to improve postprandial glycaemic control in pregnant and non-pregnant women (of reproductive age) with T1DM, and the mechanisms underlying these metabolic responses.

Read the detailed description

Poor glycaemic control in pregnancy is a major factor leading to obstetric complications and future maternal-offspring diseases (e.g., macrosomia, diabetes). This phenomenon is evidenced in women with type 1 diabetes (T1DM), and is worrisome since it is aggravating the disease burden of this and next generations. Therefore, to find strategies aimed at breaking this intergenerational cycle has become a high-priority. Exercise is a promising tool to improve short-term glycaemic responses such as postprandial glucose peaks and glucose variability, and thus reduce adverse maternal-neonatal outcomes. However, it is unknown which timing of exercise is more effective to optimise postprandial glycaemic control in pregnant women with T1DM, and non-pregnant women (of reproductive age) with T1DM. The mechanisms underlying these benefits in T1DM and pregnancy are also to be established.

The MERIT1D project will unravel which timing of exercise (before or after a meal at lunchtime) is more effective to optimise postprandial glycaemic control in pregnant and non-pregnant women with T1DM, and the mechanisms underlying these metabolic responses. Ten pregnant women with T1DM and ten non-pregnant women with T1DM will be involved in this randomised controlled crossover trial.

Pregnant women at gestational week 16 and 35 (experimental phases 1 and 2, respectively), and non-pregnant peers once after recruitment (experimental phase 1), will undergo 3 experimental conditions within 10 days (random order): pre-meal exercise, post-meal exercise, and non-exercise meal.

Each experimental phase will entail participants attending 4 times to the research centre. Therefore, pregnant women will come to the research centre for a total of 8 study visits, while non-pregnant women will come only to 4 study visits. The acute exercise stimulus will consist of a well-controlled submaximal walking test. The standardised meal provided will consist of a mixed milkshake equivalent to the 35 % of their resting energy expenditure, being made up of approximately 45% carbohydrates, 35% fat, and 20% proteins. Postprandial glycaemic responses will be continuously monitored using last-generation glucose monitoring systems during the 10-day period. Immunometabolic markers (e.g., lipids, cytokines) will be determined in maternal blood and placenta samples.

The MERIT1D study will contribute to the understanding of exercise timing in T1DM and pregnancy, and its underlying mechanisms. This will translate into a better clinical prediction, diagnosis, prognosis and treatment of glycaemic dysregulations, and into more effective exercise programmes for pregnant and non-pregnant women with T1DM.

02

Conditions studied

  • Pregnancy in Diabetic
  • Type 1 Diabetes
03

In context

Pregnancy in Diabetics

46 studies on the registry are indexed under Pregnancy in Diabetics; 16 are open to participants now.

This study's enrollment of 20 is below the median of 95 across 24 interventional studies indexed under Pregnancy in Diabetics.

Browse Pregnancy in Diabetics studies →

Lead sponsor

University of Graz is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women and non-pregnant women with T1DM aged 20-40 years
  • Having a of 18-29.9 kg/m2 at pre-pregnancy (pregnant women) or recruitment (non-pregnant)
  • Clinical diagnosis of T1DM, or/and multiple daily insulin injections for >1 year, and/or using insulin pump therapy (open-loop).
  • Willingness to provide to participate in the MERIT1D study.
  • Being able to read and speak German, English or Spanish well enough to completely understand the instructions, provide informed consent and conduct the experimental procedures.

Exclusion criteria

Exclusion Criteria:

  • Having poor glycaemic control >10% (86 mmol/mol).
  • Recurrent severe hypoglycaemia; hospitalisation for diabetic ketoacidosis during the last year.
  • Women who smoke or drink alcohol frequently, or require complex diets.
  • Having polycystic ovarian syndrome, poorly controlled asthma/allergy, uncontrolled thyroid diseases or hypertension, diabetic ketoacidosis, , , .
  • Having severe /immunodeficiency, macrovascular, renal, or neuromuscular disease, or severe retinopathy or neuropathy.
  • Having any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric, or terminal disease, or any other acute/chronic disorder that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the protocol, or that would directly influence the study results.
  • Use of any medication (e.g., ), that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results.
  • Any condition that would interfere with compliance or the results, as judged by the Investigator
  • Pregnant women: having multiple pregnancy
  • Pregnant women: evidence of incompetent cervix, ruptured membranes, placenta previa, foetal malformation, or foetal death.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Pregnant women with type 1 diabetes

    Participants will undergo 3 experimental conditions in random order at week of gestation 16 and 35 (experimental phases 1 and 2): pre-meal exercise, post-meal exercise, and non-exercise meal.

    Other: Exercise and meal testing (acute stimuli)

  • Experimental
    Non-pregnant women with type 1 diabetes

    Participants will undergo 3 experimental conditions in random order after recruitment (experimental phase 1): pre-meal exercise, post-meal exercise, and non-exercise meal.

    Other: Exercise and meal testing (acute stimuli)

Interventions

  • OtherExercise and meal testing (acute stimuli)

    Pre-meal exercise: 1º milkshake intake + 2º exercise test Post-meal exercise: 1º exercise test + 2º milkshake intake Non-exercise meal: Only milkshake intake

06

What researchers measure

Primary outcomes

  1. Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition

    * T1DM non-pregnant women, euglycemic range: 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women, euglycemic range: 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  2. Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition

    * T1DM non-pregnant women: 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women: 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

Secondary outcomes

  1. Percentage of time spent in hypoglycemia for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  2. Percentage of time spent in hypoglycemia for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  3. Percentage of time spent in hyperglycemia for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  4. Percentage of time spent in hyperglycemia for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  5. Differences in postprandial glucose levels 1-, 2-, and 4-hours post-experiment

    Within-change in glucose values (mmol/L) from pre-experiment (before starting exercise/meal testing) to post-experiment (i.e., 1-, 2-, and 4-hours after starting exercise/meal intake) in each experimental day

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 4 h/day)

  6. Differences in postprandial glucose levels 1-, 2-, and 4-hours post-experiment

    Within-change in glucose values (mmol/L) from pre-experiment (before starting exercise/meal testing) to post-experiment (i.e., 1-, 2-, and 4-hours after starting exercise/meal intake) in each experimental day

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 4 h/day)

  7. Number of hypoglycaemic events for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  8. Number of hypoglycaemic events for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \< 3.9 mmol/L (\< 70 mg/dL). * T1DM pregnant women - range: \< 3.5 mmol/L (\< 63 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  9. Number of hyperglycaemic events for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  10. Number of hyperglycaemic events for the 24 hours after each experimental condition

    * T1DM non-pregnant women - range: \> 10 mmol/L (\> 180 mg/dL). * T1DM pregnant women - range: \> 7.8 mmol/L (\> 140 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  11. Percentage of time spent in nocturnal euglycemia within each experimental day

    * T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 00:00 am - 05:59 am)

  12. Percentage of time spent in nocturnal euglycemia within each experimental day

    * T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 00:00 am - 05:59 am )

  13. Percentage of time spent in diurnal euglycemia within each experimental day

    * T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 6.00 am - 23:59 am)

  14. Percentage of time spent in diurnal euglycemia within each experimental day

    * T1DM non-pregnant women - range: euglycemia 3.9 - 10 mmol/L (70 - 180 mg/dL). * T1DM pregnant women - range: euglycaemia 3.5 - 7.8 mmol/L (63 - 140 mg/dL).

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 6.00 am - 23:59 am)

  15. Area under the curve of glycaemic exposure

    Area under the curve of glycaemic exposure during the 2, 4 and 8 hours after meal intake at each experimental condition.

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 8 hours/day)

  16. Area under the curve of glycaemic exposure

    Area under the curve of glycaemic exposure during the 2, 4 and 8 hours after meal intake at each experimental condition.

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 8 h/day)

  17. Glycaemic variability (standard deviation)

    Standard deviation (SD) of the mean continuous glucose monitoring levels over the 24 hours after each experimental condition

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  18. Glycaemic variability (standard deviation)

    Standard deviation (SD) of the mean continuous glucose monitoring levels over the 24 hours after each experimental condition

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  19. Glycaemic variability (coefficient of variation)

    Coefficient of variation of glucose levels over the 24 hours after each experimental condition

    Time frame: assessed in the study phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 24 hours/day)

  20. Glycaemic variability (coefficient of variation)

    Coefficient of variation of glucose levels over the 24 hours after each experimental condition

    Time frame: assessed in the study phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 24 h/day)

  21. Maternal glucose metabolism

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the glucose-insulin axis will be analysed (i.e., glucose, insulin, C-peptide and HbA1c).

    Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)

  22. Maternal glucose metabolism

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the glucose-insulin axis will be analysed (i.e., glucose, insulin, C-peptide and HbA1c).

    Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)

  23. Maternal lipid profile

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the lipid profile will be analysed (i.e., total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL-cholesterol, triglycerides and free fatty acids).

    Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)

  24. Maternal lipid profile

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to the lipid profile will be analysed (i.e., total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL-cholesterol, triglycerides and free fatty acids).

    Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)

  25. Maternal inflammatory markers

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to inflammatory-immunological responses will be analysed (e.g., IL-6, IL-8, IL-1β, TNFα, C-reactive protein, IFNγ)

    Time frame: assessed in the phase 1 (10 days) - at visit nº 2, 3, 4 (3 days, 3 h/day)

  26. Maternal inflammatory markers

    Fasting and post-experiment blood samples will be collected using venous puncture in the antecubital vein. Metabolic markers related to inflammatory-immunological responses will be analysed (e.g., IL-6, IL-8, IL-1β, TNFα, C-reactive protein, IFNγ)

    Time frame: assessed in the phase 2 (only pregnant women, 10 days) - at visit nº 6, 7, 8 (3 days, 3 h/day)

  27. Placenta weight

    Placenta weight (grams)

    Time frame: assessed at birth - 30 minutes

  28. Placenta biopsies

    Eight biopsies will be collected, four on the maternal site and four on the fetal side. Relevant placental proteins (growth factors and cytokines) related to insulin signalling, glucose metabolism, and inflammation will be analysed (e.g., GM-CSF, GCSF, MCP1, TNF-α, IL-6, EGF, IFN-γ, IL-8, IL-10, IL-1β).

    Time frame: collected at birth - 1 hour

  29. Neonate weight

    Neonate weight (grams)

    Time frame: assessed at birth - 5 minutes

  30. Placenta efficiency

    Neonate weight divided by placenta weight

    Time frame: estimated after birth - 3 minutes

Other outcomes

  1. Placenta completeness

    The number of present and missing cotyledons and velamentous vessels will be examined visually in all the quadrants.

    Time frame: assessed at birth - 20 minutes

  2. Neonate height

    Neonate height (cm)

    Time frame: assessed at birth - 5 minutes

  3. Neonate ponderal index

    Neonate weight/height ratio: 100 x weight / (Height)3

    Time frame: estimated after birth - 3 minutes

  4. Neonate anthropometrics

    Neonate head and abdomen circumference (cm). These circumferences will be measured using a stretch-resistant measuring tape.

    Time frame: assessed at birth - 10 minutes

  5. Neonate Apgar score

    Neonate Apgar score (1-10). The higher score is indicative of a better health status of the newborn after birth

    Time frame: assessed at birth - 5 minutes

  6. Small for gestational age

    Newborns will be diagnosed as small for gestational age newborns if their birth weight is lower than the 10th percentile for their gestational age

    Time frame: assessed after birth - 5 minutes

  7. Large for gestational age

    Newborns will be diagnosed as large for gestational age newborns if their birth weight is greater than the 90th percentile for their gestational age

    Time frame: assessed after birth - 5 minutes

  8. Physical fitness (muscle strenght)

    Upper body muscle strength will be measured by the handgrip strength test.

    Time frame: assessed in the phase 1, at visit nº 1 (10 minutes)

  9. Physical fitness (muscle strenght)

    Upper body muscle strength will be measured by the handgrip strength test.

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (10 minutes)

  10. Physical fitness (flexibility)

    Upper body flexibility will be assessed by the back scratch test, measuring the distance or overlap between the middle fingers of both hands behind the back.

    Time frame: assessed in the phase 1, at visit nº 1 (10 minutes)

  11. Physical fitness (flexibility)

    Upper body flexibility will be assessed by the back scratch test, measuring the distance or overlap between the middle fingers of both hands behind the back.

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (10 minutes)

  12. Physical fitness (cardiorespiratory fitness)

    Cardiorespiratory fitness will be assessed using a submaximal walking treadmill test while recording gas exchange data (breath by breath system).

    Time frame: assessed in the phase 1, at visit nº 1 (30 minutes)

  13. Physical fitness (cardiorespiratory fitness)

    Cardiorespiratory fitness will be assessed using a submaximal walking treadmill test while recording gas exchange data (breath by breath system).

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (30 minutes)

  14. Resting energy expenditure

    Gas exchange will be measured breath by breath using a portable gas analyser

    Time frame: assessed in the phase 1, at visit nº 1 (2 hours)

  15. Physical activity

    Physical activity levels will be measured with triaxial accelerometry.

    Time frame: assessed in the phase 1 - 10 continuous days

  16. Physical activity

    Physical activity levels will be measured with triaxial accelerometry.

    Time frame: assessed in the phase 2 (only pregnant women) - 10 continuous days

  17. Vital signs (systolic and diastolic blood pressure)

    Systolic and diastolic blood pressure (mmHg) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.

    Time frame: assessed in the phase 1, at visit nº 1 (15 minutes)

  18. Vital signs (systolic and diastolic blood pressure)

    Systolic and diastolic blood pressure (mmHg) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (15 minutes)

  19. Vital signs (resting heart rate)

    Resting heart rate (beats per minute) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.

    Time frame: assessed in the phase 1, at visit nº 1 (15 minutes)

  20. Vital signs (resting heart rate)

    Resting heart rate (beats per minute) will be assessed twice using an upper arm digital sphygmomanometer with women seated, relaxed and not talking.

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (15 minutes)

  21. Initial anamnesis (sociodemographic and clinical information)

    Relevant information from the patients will be collected by the physicians who will ask them, and by an initial questionnaire prepared by the researchers (e.g., age, educational level, occupational status, medications, diseases, etc.).

    Time frame: assessed in the phase 1, at visit nº 1 (40 minutes)

  22. Sleep quality (questionnaire)

    The sleep quality will be assessed using a validated questionnaire, the Pittsburgh Sleep Quality Index questionnaire (PSQI). Higher scores indicate worse sleep quality (0-21).

    Time frame: assessed in the phase 1, at visit nº 1 (20 minutes)

  23. Sleep quality (questionnaire)

    The sleep quality will be assessed using a validated questionnaire, the Pittsburgh Sleep Quality Index questionnaire (PSQI). Higher scores indicate worse sleep quality (0-21).

    Time frame: assessed in the phase 2 (only pregnant women), at visit nº 5 (20minutes)

07

Study locations

1 site
  • University of Graz
    Graz, Styria 8010, Austria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Sep 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
May 6, 2023
StartActual
Jun 22, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05843175
Lead sponsor
University of Graz
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jun 22, 2023
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Dec 17, 2025

Study contacts

Pedro Acosta-Manzano, PhD
principal investigator · University of Graz
Mireille van Poppel
principal investigator · University of Graz

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion